Alexander disease results from gain of function mutations in the gene encoding glial fibrillary acidic protein (GFAP), an intermediate filament protein expressed in astrocytes. At least eight GFAP isoforms have been described, however, the predominant alpha isoform accounts for approximately 90% of GFAP protein in the central nervous system. Here we describe exonic variants identified in three unrelated families with Type II Alexander disease that alter the splicing of GFAP pre-mRNA and result in upregulation of a previously uncharacterized GFAP lambda isoform (NM 001363846.1). Affected members of Family 1 and Family 2 shared the same missense variant, NM 001363846.1:c.1289G>A;p.(Arg430His) while in Family 3 we identified a synonymous variant in the adjacent nucleotide, NM 001363846.1:c.1290C>A;p.(Arg430Arg). Using RNA and protein analysis of brain autopsy samples, and a mini-gene splicing reporter assay, we demonstrate both variants result in upregulation of the lambda isoform. We assessed other GFAP variants in the ClinVar database for predicted aberrant splicing and using the same assay demonstrated significant changes to splicing for two selected variants. Our approach demonstrates the importance of characterizing the effect of GFAP variants on mRNA splicing in order to inform future pathophysiologic and therapeutic study for Alexander disease.
Main Text
Glial fibrillary acidic protein (GFAP), encoded by GFAP (OMIM: 137780), is an 1 intermediate filament protein that is highly expressed by astrocytes in the central 2 nervous system. Pathogenic variants in GFAP are associated with Alexander Disease 3 (AxD [OMIM:203450]), an autosomal dominant leukodystrophy characterized primarily 4 by astrocyte dysfunction [17] . The majority of AxD associated variants are missense 5 variants in coding regions of the predominant GFAP isoform, GFAP-alpha (GFAP-α) 6 and are thought to exert a dominant toxic gain of function. To our knowledge, there 7 have only been three reported cases of AxD resulting from variants affecting GFAP 8 mRNA splicing [3] [4] [5] . 9 AxD is divided into two forms based on the age of onset and symptom complex [15, 18] . 10 AxD Type I is an early childhood onset leukodystrophy with macrocephaly, spasticity, 11 seizures, psychomotor regression, and bulbar dysfunction eventually culminating in early 12 childhood demise. Type II AxD is typically seen in older children and adults, with a 13 clinical presentation of autonomic dysfunction, gait dysfunction, and bulbar symptoms 14 including palatal tremor/myoclonus and oculomotor abnormalities. Type II AxD has a 15 more favorable prognosis, with a median survival of 25 years versus 14 years for type I 16 AxD [15] . 17 In this study, we report three families with a clinical presentation consistent with Type 18 II AxD that have variants in a shared exon of the epsilon isoform of GFAP and a previously 19 uncharacterized GFAP isoform (NM 001363846.1). Family 1 and Family 2 share the 20 same missense variant, NM 001363846.1:c.1289G>A; p.(Arg430His), while Family 3 21 has a synonymous variant in the adjacent nucleotide, NM 001363846.1:c.1290C>A; 22 p.(Arg430Arg). Using a mini-gene splicing reporter assay together with RNA and 23 protein analysis of brain autopsy samples, we demonstrate that both variants result in 24 aberrant splicing of GFAP pre-mRNA. 25 Informed consent for all participating individuals was obtained under IRB approvals 26 by the Institutional Review Board at the Children's Hospital of Philadelphia. Protein 27 expression studies were performed under institutional review board approvals from the 28 University of Alabama at Birmingham, Albert Einstein College of Medicine, and the 29 University of Wisconsin-Madison.
30
Family 1 has a five-generation pedigree that includes more than 20 affected individuals 31 with a phenotype consistent with Type II AxD. Analysis of their clinical data (Table 32 1) suggests that affected individuals presented most commonly with gait dysfunction 33 (12/16), bulbar dysfunction manifesting as swallowing difficulties, choking, or dysarthria 34 (7/16), and extremity paresthesias (4/16). The average age of onset was 42 years of 35 age (range: 20 -66 years). MRI, performed in 6 individuals, showed T 2 hyperintensity 36 in the brainstem in all cases, often affecting the medulla (6/6). Significant atrophy of 37 the medulla was seen in two of these. Autopsy performed in two affected individuals 38 demonstrated the hallmark neuropathologic features of AxD, including Rosenthal fibers 39 and astrogliosis. A constellation of clinical tests indicative of a cause of their neurologic 40 disease across different members of this family was unrevealing, yet the family history of 41 dominantly-inherited disease and clinical features including neuropathologic confirmation 42 consistently suggested a diagnosis of AxD ( Figure 1A and Table 1 [10] , with a clinical presentation suggestive of adult-onset AxD, that was 45 confirmed by autopsy, but for whom a causative GFAP variant had not been detected. 46 He presented at 45 years of age with gait dysfunction, dysarthria, and upper motor 47 neurological signs. There was also significant family history, with three siblings found to 48 also be clinically affected with features consistent with Type II AxD.
49
Family 3 consists of a female proband and her affected father, with a disease phenotype 50 suggestive of Type II AxD ( Table 1 ). The proband had disease onset at 10 years of age, 51 with headaches, bulbar dysfunction, failure to thrive, gastric dysmotility, and seizures. 52 MRI was consistent with AxD ( Figure 1A) , with notable T 2 signal abnormalities in 53 the brainstem (medulla and pons) and the frontal horns of the lateral ventricles as well 54 as mass-like lesions along the brainstem. The father's MRI demonstrated a brainstem 55 lesion and he has had increasing difficulties in gait and swallowing, as well as autonomic 56 dysfunction, dysarthria and sleep apnea as commonly seen in Type II AxD. Segregation analysis by Sanger sequencing confirmed that all six tested members of 64 Family 1 with clinical symptoms were heterozygous for the c.1289G>A variant. In Family 65 3, segregation analysis confirmed the proband's affected father was also heterozygous for 66 the c.1290C>A variant.
67
In healthy central nervous system tissue, approximately 90% of GFAP protein is 68 derived from the predominant GFAP-α isoform (NM 002055.5) [12] . At least seven 69 other GFAP isoforms have also been described, including the GFAP epsilon isoform 70 3/11 (GFAP-; NM 001131019.3), also known as the delta isoform (GFAP-δ); as well as the 71 kappa isoform (GFAP-κ; NM 001242376.2) [1] . The initial 390 amino acids are identical 72 in all major GFAP isoforms, and differ only in their make-up of the C-terminal region 73 (Figure 2A-B ).
74
The c.1289G>A and c.1290C>A variants identified in this manuscript are both 75 situated in an exon shared by GFAP-(exon 7A) and the transcript NM 001363846.1, 76 hereafter referred to as GFAP-λ (Figure 2A-B) . The GFAP-λ transcript is present in the 77 RefSeq mRNA database [14] , but to our knowledge has not previously been described in 78 the AxD or GFAP literature. The exon containing c.1289G>A and c.1290C>A is not 79 included in the predominant GFAP-α isoform.
80
The c.1289G>A variant has been previously described in several cases; a sibling pair 81 with adult-onset AxD [11] , and two descriptions of single, unrelated individuals in Karp 82 et al. and Pinto e Vairo et al. [9, 13] (Table 1 ). It is possible that the patient reported by 83 Pinto e Vairo et al. (2018) is related to the individuals we have studied in Family 1, and 84 hence not an independent occurrence of this variant [13] . In the study by Melchionda et 85 al., it was hypothesized that the pathogenic effect of the c.1289G>A variant resulted 86 from perturbation of the GFAP network by inefficiently incorporated GFAP-Arg430His 87 protein [11] . 88 Single Molecule Array (Simoa; Quanterix), a digital ELISA assay, was used to 89 quantitate GFAP levels in blood plasma of individuals from both Family 1 and Family 90 3. Individuals affected by AxD are known to have highly elevated levels of GFAP in 91 plasma [8] . We found individuals heterozygous for either the c.1289G>A (Family 1) or 92 the c.1290C>A (one individual in Family 3) variants demonstrated significantly elevated 93 blood plasma GFAP levels relative to controls (p=0.0001) ( Figure 1B ).
94
Given that Families 1 and 2 have a single nucleotide variant adjacent to that of 95 Family 3, only the former of which is predicted to result in a change to an encoded 96 protein sequence, we hypothesized that these variants may have a deleterious impact 97 through influencing the splicing of GFAP pre-mRNA. To address this possibility, we 98 generated a mini-gene splicing reporter by cloning 8.1kb of GFAP genomic sequence into 99 the mammalian expression vector pEYFP-C1. Primer directed mutagenesis was used to 100 generate versions of the plasmid containing the c.1289G>A and c.1290C>A variants 101 before transfection into HEK cells.
102
Amplification by reverse transcription-PCR (RT-PCR) using a forward primer in exon 103 5 and a reverse primer in exon 8 yielded an amplicon consistent with the size expected 104 from GFAP-α using RNA isolated from cells transfected with either the wild-type or 105 the mutant plasmids ( Figure 2C ). However, an additional, approximately 100 nt larger 106 amplicon was also generated from the cells transfected with either the c.1289G>A or 107 c.1290C>A mutant plasmids that is absent from cells transfected with the wild-type 108 plasmid ( Figure 2C ). Sanger sequencing revealed that the larger amplicon is due to the 109 presence an additional exon, hereafter referred to as exon 7C, between exon 7 and exon 110 8, consistent with the GFAP-λ isoform ( Figure 2C and Supplemental Figure S1 ).
111
RNA extracted from brain autopsy samples from a deceased member of Family 1 112 was used to confirm the presence of the aberrantly spliced transcript. Primers located 113 in exons 6 and 9 of GFAP-α amplified a fragment of the expected size for a GFAP-α 114 template from both patient and control brain RNA samples ( Figure 3A) . The patient 115 RNA also generated a larger amplicon consistent with the GFAP-λ splicing variant noted 116 above ( Figure 3A) . Using a primer pair specific to GFAP-λ, we confirmed its presence in 117 the patient sample. The GFAP-λ splice variant was also detected in the control sample, 118 although it was noticeably less abundant ( Figure 3A) . Sanger sequencing confirmed the 119 identity of these amplicons ( Figure 3B ).
120
The GFAP-λ transcript is equivalent to GFAP-α with an additional 120nt exon 121 (exon 7C) inserted between exons 7 and 8 (Figure 2A 
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consists of the first 430 (of 431) residues of GFAP-followed by the terminal 42 residues 125 GFAP-α. 126 To determine if the GFAP-λ mRNA is translated into a stable protein, we performed 127 western blot analysis on protein isolated from a brain autopsy sample from the proband 128 of Family 2. The blot was probed with an available antibody to an epitope in exon 129 9 of GFAP-α, which should recognize GFAP-α and GFAP-λ, but not GFAP-, and a 130 separate antibody to an epitope in exon 7A of GFAP-, which should recognize GFAP-131 and GFAP-λ, but not GFAP-α. Blots confirming the specificity of these antibodies were 132 performed with recombinant GFAP-α and GFAP-( Figure 3C ). In intermediate filament 133 enriched protein fractions, the expected 50 kD GFAP-α and 49.5 kD GFAP-are clearly 134 present in the Family 2 patient as well as three unrelated AxD controls ( Figure 3D) . In 135 the individual from Family 2, a larger band is clearly visible that appears to cross react 136 with both antibodies. This band is not present in any of the other AxD affected samples 137 serving as controls and is consistent with the predicted protein encoded by GFAP-λ (54 138 kD) that contains the C-terminal regions of both GFAP-α and GFAP-.
139
Based on the hypothesis that alteration of splicing might be a broader mechanism 140 of pathogenesis in AxD, we reviewed GFAP variants recorded in ClinVar and used 141 SpliceAI [7] to predict if they were likely to alter splicing, identifying two variants 142 strongly predicted to do so. NM 002055.5:c.1171+5G>A (ClinVar ID:323610; located 143 5 nt into the start of GFAP-α intron 7), is predicted to weaken the exon 7 splice 144 donor site, which could favor formation of the kappa isoform ( Figure 2B ). The second 145 variant, NM 002055.5:c.731C>T;p.(Ala244Val) (ClinVar ID: 66500), has been associated 146 with Type I AxD and classified as pathogenic on the basis of clinical findings despite 147 inconclusive functional testing [10] . SpliceAI predicts this variant will strengthen a 148 cryptic splice donor site within exon 4, truncating the final 17 amino acids of the exon 149 while maintaining the reading frame. We interrogated each of these variants using our 150 GFAP mini-gene splicing reporter assay and confirmed that each of the variants induced 151 the predicted change in GFAP splicing ( Figure 2C -E and Supplemental Figure S2 ).
152
In this study, we demonstrate that the GFAP variants c.1289G>A and c.1290C>A 153 both result in a substantial alteration in the splicing of GFAP and an upregulation 154 of a previously undescribed isoform, GFAP-λ. Previous in vitro studies have shown 155 that overexpression of GFAP-induces changes to intermediate filament networks 156 and increases associations with cellular stress proteins such as αB-crystallin [12] . In 157 Vanishing White Matter Disease (OMIM:603896), an autosomal recessive leukodystrophy 158 also characterized by astrocytic dysfunction, in vivo models and neuropathology have 159 revealed significantly increased GFAP-and dysmorphic astrocytes, likely affecting 160 trophic support to developing oligodendrocytes [2, 19] . Given GFAP-is a truncated 161 version of GFAP-λ, we suggest that the increase in GFAP-λ is likely to result in a 162 similar perturbation of the GFAP network. Although we cannot discount the possibility 163 that the p.(Arg430His) missense change in GFAP-is also deleterious (as suggested 164 by Melchionda et al. (2013) ), our finding of an adjacent synonymous c.1290C>A; 165 p.(Arg430Arg) variant in Family 3 suggests that alteration of GFAP splicing is likely to 166 be the primary functional consequence of both of these AxD associated variants.
167
Type II AxD is characterised typically by a later age of onset but can be variable, as 168 evidenced by the juvenile onset disease seen in an affected individual of Family 3. Thus, 169 evaluating the penetrance of particular pathogenic variants can be challenging. A full 170 understanding of the penetrance of the variants discussed in this manuscript will require 171 larger segregation studies and longer longitudinal follow-up.
172
It was recently demonstrated that antisense suppression using targeted oligonu-173 cleotides in a murine model of AxD attenuated and reversed the overexpression of Gfap 174 and lowered tissue and cerebrospinal fluid GFAP protein levels, providing a promising 175 therapeutic approach for this disorder [6] . Antisense approaches have demonstrated 176 benefit in other disorders with a gain-of-function mechanism, and appropriate design 177 must take into account variant consequences, including aberrant splicing [16] . The results 178 7/11 presented in this manuscript suggest that selective suppression of individual isoforms 179 might be a future avenue for therapeutic development for AxD cases associated with 180 aberrant splicing.
181
In summary, while the majority of variants causing AxD are missense variants in 182 coding regions, we provide further evidence that aberrant splicing due to exonic and 183 intronic variants in GFAP is likely to contribute to a fraction of AxD cases. Our study 184 illustrates the importance of considering the effect of GFAP variants on mRNA splicing 185 to ensure accurate diagnosis, and to appropriately plan future therapeutic approaches 186 for affected individuals. 
187
Y N Y Y Y Y Dysfunction Peripheral Neuropahy N/A N/A N N/A N Y N Autonomic Dysfunction N/A N/A N N/A N N N Seizures N/A N/A Y N/A N N N Bulbar Dysfunction Y (7/16) Y Y N/A Y Y Y
